Corindus Vascular Robotics Gets FDA Conditional Approval for Pivotal Study

Corindus Vascular Robotics, a leading developer of precision vascular robotics, Wednesday announced it has been granted Food and Drug Administration (FDA) conditional Investigational Device Exemption approval to evaluate the safety and effectiveness of its CorPath 200 System in delivering and manipulating coronary guidewires and stent/balloon systems in percutaneous coronary intervention procedures.
Morningstar